Tibsovo Gets A Win In AML Following Servier Takeover

Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.

Acute myeloid leukemia a 3d-Render
Servier announced results from the Phase III AGILE study of Tibsovo in IDH1-mutant AML • Source: Shutterstock

Les Laboratoires Servier SAS has added to a string of incremental wins for the drug Tibsovo (ivosidenib) since the company bought the rights from Agios Pharmaceuticals, Inc. near the end of 2020, with new positive topline Phase III results in acute myeloid leukemia (AML), though it will be entering a field with steep competition.

Paris-based Servier said 2 August that topline results of AGILE showed that Tibsovo combined with Bristol Myers Squibb Company’s...

More from Clinical Trials

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

More from R&D

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.